
## Interim results presentation



For the period ended 31 January 2023



possibilities

#### **DISCLAIMER**



The following presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated ("relevant persons"). Any person who is not a relevant person should not act or rely on this presentation or any of its contents. This presentation does not constitute an offering of securities or otherwise constitute an invitation or inducement to any person to underwrite, subscribe for or otherwise acquire securities in Nanoco Group PLC or any of its subsidiaries ("Nanoco").

It should be noted that past performance cannot be relied on as a guide to future performance. This presentation contains forward-looking statements with respect to Nanoco's plans and objectives regarding its financial conditions, results of operations and businesses.

The financial information referenced in this presentation does not contain sufficient detail to allow a full understanding of Nanoco's Interim Results. For more detailed information, the entire text of the Interim Results announcement for the six months ended 31 January 2023, can be found on the Investor Relations section of the Nanoco website (<a href="www.nanocogroup.com">www.nanocogroup.com</a>).

# HIGHLIGHTS – SIGNIFICANT OPPORTUNITIES NANOCO



Final validation underway for commercial production materials

Significant forecast growth in core markets

Litigation validated the Group's core IP

Litigation proceeds underpin commercial business

### **VALUE OPPORTUNITIES**



# Sensing

Service and product revenue potential

Multiple material validations FY23

Order visibility target H2 CY23

Strong progress

# Display

Service, product and licensing potential

Increase engagement with display companies

Leverage validated core IP into new licenses

Improving outlook

**Underpinning core IP** 

ΙP



## **BUSINESS REVIEW - SENSING**

### IR SENSING OPPORTUNITIES



#### The Problem

- Poor IR efficiency of silicon sensors
- Interference from natural light
- Impacted by atmospheric conditions
- Uses more power in mobile devices
- InGaAs alternatives very expensive

#### Why Quantum Dots

- Expand sensor range into infra red
- Overcomes sunlight issues
- Penetrates atmospheric conditions
- Reduces mobile device power needs
- CMOS+QD can be over 100x cheaper

#### Nanoco's Differentiation

- Proven data capture efficiency (~10x)
- Large production capability in place
- Wide range materials
- Multiple tunable wavelengths
- IP protected platform technology

#### Quality control



Fog/smog



Driver monitoring



Surveillance




Digital healthcare



Security

Iris recognition



Agriculture










Huge growing range of high value added applications for NIR / SWIR

#### HIGH GROWTH SENSING MARKETS



#### Image sensor market expected to surpass \$30bn by 2030\*



- Growth in sensors driven by mobile, industrial, automotive applications
- Technology supports drive for new materials to increase speed and sensitivity - QDs
- Cost a key driver for high volume applications - QDs

New materials key to performance gains for new applications

### SENSING PRODUCT DEVELOPMENT



| Early 2018  |    | NIR     |   | SWIR           |   |   |               |   |   |           |   |   |
|-------------|----|---------|---|----------------|---|---|---------------|---|---|-----------|---|---|
| Wavelength  | (- | <1.0 µm | ) | (1.0 – 1.3 µm) |   |   | (1.3 -1.5 µm) |   |   | (>1.5 µm) |   |   |
| Material    | А  | В       | С | А              | В | С | А             | В | С | А         | В | С |
| Development | 1  |         |   |                |   |   |               |   |   |           |   |   |

Strong progress expanding wavelengths and base materials

| January 2023 |           | NIR |                | SWIR |   |               |   |   |           |   |   |   |
|--------------|-----------|-----|----------------|------|---|---------------|---|---|-----------|---|---|---|
| Wavelength   | (<1.0 µm) |     | (1.0 – 1.3 µm) |      |   | (1.3 -1.5 µm) |   |   | (>1.5 µm) |   |   |   |
| Material     | Α         | В   | С              | Α    | В | С             | Α | В | С         | Α | В | С |
| Development  | 1         | 2   |                |      | 2 |               | 1 | 2 | 1         |   |   |   |
| Optimisation |           |     |                |      |   |               |   |   |           |   |   |   |
| Scale Up     |           |     |                |      |   |               |   |   |           |   |   |   |
| Validation   |           |     |                |      |   |               | 1 |   |           |   |   |   |
| Production   |           |     |                |      |   |               |   |   |           |   |   |   |

#### Legend (# = number of customers)

- # Development material at R&D scale
- # Optimisation application optimisation
- # Scale Up scaling up at Runcorn
- # Validation material ready for validation
- # Production ready for production: goal
- Change / major progress in Period

Sensing goals: production orders and two validated materials 2023




## **BUSINESS REVIEW - DISPLAY**

## **QD DISPLAY MARKETS – TV**



#### QD share of flat panel TV market rises from~6% to ~34%




Nanoco validated IP to access expanding purple wedge of 'Other QD TVs'

## **QD DISPLAY MARKETS – OTHER DEVICES**



#### Significant growth forecast in other devices using QD technology



Smaller devices in high numbers equivalent to 30% of QD TV area by 2030

## NANOCO CFQD ® OPPORTUNITIES



- Significant growth forecasts for QD TVs, 38% CAGR to 2030
- Validated IP creates a significant technical and financial barrier to entry
- Nanoco CFQD® cadmium free quantum dots on test with a major TV brand
- Runcorn production capacity enough for new entrant volumes (few million TVs)
- RoHS concerns still pushing ESG agenda towards cadmium free solutions
- Exploring distribution agreement with potential Chinese partner
- Low cost to scale production capacity if required



## IP TRANSACTIONS

### **IP TRANSACTIONS – FINANCIALS**



## Total \$150m

- · Nanoco share \$90.0m (pre-tax)
- Funder + adviser costs \$60.0m

## Tranche 1 \$75m

- Received March 23
- · Funder + advisers \$60.0m
- · Nanoco \$15.0m (pre-tax)

## Tranche 2 \$75m

- Due by February 24
- Nanoco \$75.0m (pre-tax)
- · Balance business needs and return of capital

### IP TRANSACTIONS - ACCOUNTING



- Structured as a Sale of IP <u>and</u> an IP Licence
- Retain full freedom to operate in all products, markets, and geographies
  - Retain all patents linked to current commercial activity
  - Licence back on disposed patents (industry standard)
  - Sale of 118 non-core, non-material patents (book value £0.4m)
- Disposal recognised in FY23 as a profit on disposal of intangible assets
- IP Licence granted over retained IP portfolio
- Income recognised over next ~nine years reflecting ongoing access to IP portfolio
- Global settlement of all litigation
- Proceeds can be offset against ~£43m UK losses. Final cash tax impact ~£5.0m\*

### **BOARD LITIGATION RISK ASSESSMENT**





Risk adjusted NPV assessments discount a 'perfect' outcome

#### **FUTURE LICENSING OPPORTUNITIES**



- US PTAB validated Nanoco core patents
- Nanoco retain all high value core process and composition of matter patents
- Opportunity for proactive licensing approaches as QD display market grows
- IP licensing team established to identify and pursue opportunities
- Retained IP strategy expert, reviewing options for external licensing support
- Litigation proceeds create option to self-fund future licensing or litigation

Potential medium term IP income to supplement commercial business



## **FINANCIAL REVIEW**

### FINANCIAL HIGHLIGHTS



Revenue 45% up on PY driven by material sales

Cost base stable as
Manchester savings offset
inflation and additional
staff

Cash £6.0m: net monthly cash burn c. £0.1m

Tranche 1 litigation proceeds received post period end

#### **INCOME STATEMENT**




|   | H1 FY23<br>£m | H1 FY22<br>£m | Change<br>£m |
|---|---------------|---------------|--------------|
| Revenue                                     | 1.6           | 1.1           | +0.5         |
| Cost of sales                               | (0.3)         | (O.1)         | (O.2)        |
| Gross profit                                | 1.3           | 1.0           | +0.3         |
| Other operating income (grants)             | 0.1           | 0.2           | (O.1)        |
| R&D investment                              | (1.0)         | (1.0)         | -            |
| Other administrative expenses               | (1.5)         | (1.3)         | (O.2)        |
| Adjusted LBITDA                             | (1.1)         | (1.1)         | -            |
| Share based payments and associated charges | (0.5)         | (0.4)         | (O.1)        |
| Litigation costs                            | (O.1)         | -             | (O.1)        |
| Depreciation & Amortisation                 | (0.4)         | (0.6)         | +0.2         |
| Operating loss                              | (2.1)         | (2.1)         | -            |
| Tax and financing costs                     | -             | -             | -            |
| Loss after tax                              | (2.1)         | (2.1)         | -            |

- → Revenue growth partly offset by material costs for multiple production test runs
- → Administrative cost increase reflects salary inflation and recent investment in new staff
- → One off litigation costs (£0.1m) funded by Nanoco (multiple trial dates) and one off Runcorn move costs (£0.1m)

### **MOVEMENT IN NET LOSS**






- → Revenue £0.5m higher with strong operational leverage from service income
- → Opex £0.3m higher Manchester savings partly offset inflationary costs and new staff
- → Expect monthly gross cash cost base to stabilise at ~£0.4m

### **MOVEMENT IN CASH**





- → Underlying cash consumption £0.8m in the Period
- → R&D tax credit reduces as we reduce our cost base future approach may change
- → Underlying £0.1m net monthly cash burn, half the rate in H1 FY22

### **FINANCIAL SUMMARY**



#### Guidance

- · Underlying revenue 20% ahead of FY22 plus £3.0m IP license income
- · Cash costs stable at ~£0.4m per month savings offset cost increases
- · Activity levels increasing amidst preparations for commercial production

### Capability

- · Retained core capabilities through three very challenging years
- · Team grown to 44 FTE's capacity for service and product revenue
- · Investing in both Runcorn facilities

#### **Treasury**

- · Commercial business average net monthly cash burn H1 FY23 ~£0.1m
- · Cash runway no longer a concern
- · Balance sheet to be restructured to enable potential return of capital



## **SUMMARY**

# SUMMARY - SIGNIFICANT VALUE POTENTIAL GROUP



### Opportunity

- · Nanoco active in high growth global markets
- · Validated IP creates barrier to entry in display markets
- · Novel high performing materials to exploit rapid growth in sensing

#### **Platform**

- Most robust position in 20 year history
- · Core IP underpins BOTH display and sensing opportunities
- · Strength in a fully funded "risk off" market

#### Value

- · Litigation delivered transformational value for Nanoco, IP validated
- · Two materials in final pre-production validation
- · Management focus remains on commercial business



# **QUESTIONS**



## **APPENDICES**

#### **BOARD MEMBERS**



## **Dr Christopher Richards**Non-Executive Chairman

- CEO, Non-Executive chairman, Arysta LifeSciences
- 20 years of increasing management roles at Syngenta
- Chairman of Plant Health Care plc (AIM: PHC) and NED of Origin Enterprises plc (AIM: OGN)

## Brian Tenner

- Experienced Quoted Company Director with strong operational and transformation experience
- Previously Board Member and CEO / CFO of NCC Group plc, Renold Plc, Scapa Group plc, and British Nuclear Group Ltd

## **Dr Nigel Pickett**Co-founder & CTO

- Inventor of Nanoco's key patented scale-up technology
- Leading expert on semi-conducting nano-crystals
- Japanese Government, St. Andrews University, Georgia Tech

#### **Liam Gray** CFO and Company Secretary

- Chartered accountant, having qualified with KPMG
- Previously worked for a variety of listed and private entities in a range of positions

# **Dr Alison Fielding**Non-Executive (Remuneration chair)

- Astra Zeneca, followed by McKinsey & Co, then co-founded Techtran Group Limited which was acquired by IP Group in 2005 and subsequently held the role of director and COO at IP Group
- Board member / advisor of several early stage and quoted IP Group backed tech companies
- NED of Zotefoams plc, Maven Income and Growth VCT plc and Thomas Swan and Co Ltd

## **Chris Batterham**Non-Executive

(Audit chair)

- 20 years of Non-Executive experience in high growth technology companies including:
- NED of NCC Group plc
- Previously CFO of Unipalm, first Internet IPO

## SHAREHOLDER ANALYSIS (AS AT 31 January 2023)



| Name                                 | Shareholding | Percentage |
|--------------------------------------|--------------|------------|
| Hargreaves Lansdown Asset Management | 57,596,986   | 17.86      |
| Lombard Odier Investment Managers    | 38,847,752   | 12.05      |
| Interactive Investor                 | 32,197,693   | 9.99       |
| Directors                            | 12,994,799   | 4.03       |
| HSDL stockbrokers                    | 12,177,330   | 3.78       |
| Barclays Smart Investor              | 11,695,899   | 3.63       |
| Tariq Hamoodi                        | 10,866,006   | 3.37       |
| Interactive Brokers                  | 10,537,829   | 3.27       |
| Total of shareholdings above         | 186,914,294  | 57.88      |

Note: The total number of voting rights in the Company is 322,433,522 (excludes 12,222 Treasury shares)





